PCSK9 inhibition: A promise fulfilled?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Reduced proprotein convertase subtilisin/kexin type 9 (PCSK9) activity is linked to fewer cardiovascular disease (CVD) events.
• Statin therapy alone may not achieve treatment goals for all patients, necessitating add-on treatments.
• Monoclonal antibody therapies targeting PCSK9 have been developed and approved by the FDA.

Purpose of the Study:

• To summarize the current status and future expectations for PCSK9 inhibitors in cardiovascular disease management.
• To highlight the need for ongoing clinical trial data on PCSK9 inhibitors.

Main Methods:

• Review of existing clinical trial data and FDA approvals for PCSK9 inhibitors.
• Anticipation of results from ongoing long-term clinical trials.

Main Results:

• PCSK9 inhibitors are approved by the FDA for specific patient populations.
• These therapies represent a significant advancement in managing cardiovascular risk.
• Further data are needed to fully understand long-term tolerability, safety, and CVD event reduction.

Conclusions:

• PCSK9 inhibitors are a valuable addition to the therapeutic arsenal for reducing cardiovascular events.
• Continued research is crucial to establish the long-term benefits and safety profile of these novel therapies.